Company Info
| Industry | Biotechnology |
|---|---|
| Sector | Health Technology |
| Employees | 9,100 |
| CEO | Mr. Michel Vounatsos |
| Address | 225 Binney Street , Cambridge, MA 02142 |
|---|---|
| Phone | 1.617.679.2000 |
| Website | www.biogen.com |
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Competitors
| Company Name | 3 Month %Change |
1 Year %Change |
|---|---|---|
| Biogen, Inc. | -32.15% | -7.91% |
| Thermo Fisher Scientific, Inc. | 11.97% | 33.30% |
| Eli Lilly & Co. | -3.21% | 68.71% |
| Danaher Corp. | -5.86% | 40.12% |
| Abbott Laboratories | 1.03% | 21.15% |
Statement Summary
as of 4:00 ET PM 12/02/2021| Total Assets (MRQ) | 23.8 B |
|---|---|
| Total Liabilities (MRQ) | 12.9 B |
| Shareholders’ Equity (MRQ) | 10.9 B |
| Total Revenue (Annual) | 2.6 B |
| Net Income (Annual) | 329.2 M |
Earnings And Estimates
as of 4:00 ET PM 12/02/2021
| Current Qtr EPS Estimate | 3.33 |
|---|---|
| Current FY EPS Estimate | 19.16 |
| Long Term EPS Growth Estimate | -1.03 |
| Next Expected Earnings Date | // |
BIIB vs S&P 500
as of 12/02/2021| Relative To S&P 500 |
BIIB | |
|---|---|---|
| 4 Weeks | n/a | n/a |
| 12 Weeks | n/a | n/a |
| YTD | n/a | n/a |
Earnings Surprises
as of 4:00 ET PM 12/02/2021| Fiscal Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 09/2021 | 4.09 | 4.77 | +16.73% |
| 06/2021 | 4.55 | 5.68 | +24.86% |
| 03/2021 | 4.98 | 5.34 | +7.20% |
| 12/2020 | 4.79 | 4.58 | -4.42% |
| 09/2020 | 8.09 | 8.84 | +9.32% |
| 06/2020 | 8.02 | 10.26 | +27.90% |
| 03/2020 | 7.72 | 9.14 | +18.33% |
| 12/2019 | 8.03 | 8.34 | +3.90% |
Financial Strength
as of 4:00 ET PM 12/02/2021| Pre-Tax Margin | 10.99 |
|---|---|
| Net Margin | -44.74 |
| Operating Margin | 26.91 |
| Return On Equity | 14.59 |
| Return On Assets | 6.34 |
| Inventory Turnover (TTM) | 2.02 |
| Sales Growth (MRQ) | 5.80 |
Ratios
as of 4:00 PM ET 12/02/2021| Price/Earnings (TTM) | 22.36 |
|---|---|
| Price/Book (MRQ) | 3.15 |
| Price/Cash Flow (TTM) | 13.67 |
| Book Value (MRQ) | 71.00 |
| Quick Ratio (MRQ) | 1.38 |
| Current Ratio (MRQ) | 1.70 |
| Total Debt/Equity (MRQ) | 0.73 |
Short Interest
as of 4:00 PM ET 12/03/2021| % Short - 0.00% | |
| % Remaining Float - 100.00% |
| Current | Last Month | |
|---|---|---|
| Short Interest Date | n/a | n/a |
| Short Interest Shares | 0 | 0 |
| Short Interest Ratio | 0.0 | 0.0 |
M Y M Y
Total Assets 0,0.00 0,0.00
Total Liabilities 0,0.00 0,0.00
Total Equity 0,0.00 0,0.00
M Y M Y
Total Revenue 0,0.00 0,0.00
EBT Exc.
Unusual Items
0,0.00
0,0.00
Net Income 0,0.00 0,0.00
M Y M Y
Cash from
Operations
0,0.00
0,0.00
Cash from
Activities
0,0.00
0,0.00
Cash from
Fin. Activities
0,0.00
0,0.00
TOTAL ASSETS |
TOTAL LIABILITIES |
TOTAL EQUITY |
|---|---|---|
Balance Sheet
| M Y | ||||
|---|---|---|---|---|
| ASSETS | ||||
| Cash And Equivalents | 0,0.00 | |||
| Receivables | 0,0.00 | |||
| Inventories | 0,0.00 | |||
| Other Current Assets | 0,0.00 | |||
| Total Current Assets | 0,0.00 | |||
| Property, Plant & Equipment, Gross | 0,0.00 | |||
| Accumulated Depreciation & Depletion | 0,0.00 | |||
| Property, Plant & Equipment, Net | 0,0.00 | |||
| Intangibles | 0,0.00 | |||
| Other Non-Current Assets | 0,0.00 | |||
| Total Non-Current Assets | 0,0.00 | |||
| TOTAL ASSETS | 0,0.00 | |||
| Liabilities & Shareholder Equity | ||||
| Accounts Payable | 0,0.00 | |||
| Short Term Debt | 0,0.00 | |||
| Total Current Liabilities | 0,0.00 | |||
| Long Term Debt | 0,0.00 | |||
| Deferred Income Taxes | 0,0.00 | |||
| Other Non-Current Liabilities | 0,0.00 | |||
| Minority Interest | 0,0.00 | |||
| Total Non-Current Liabilities | 0,0.00 | |||
| Preferred Stock Equity | 0,0.00 | |||
| Common Stock Equity | 0,0.00 | |||
| Common Par | 0,0.00 | |||
| Additional Paid In Capital | 0,0.00 | |||
| Cumulative Translation Adjustment | 0,0.00 | |||
| Retained Earnings | 0,0.00 | |||
| Treasury Stock | 0,0.00 | |||
| Other Equity Adjustments | 0,0.00 | |||
| Total Capitalization | 0,0.00 | |||
| TOTAL EQUITY | 0,0.00 | |||
| TOTAL LIABILITIES & STOCK EQUITY | 0,0.00 | |||
| Total Common Shares Outstanding | 0,0.00 | |||
| Preferred Shares | 0,0.00 | |||
| Treasury Shares | 0,0.00 | |||
| Basic Weighted Shares Outstanding | 0,0.00 | |||
| Diluted Weighted Shares Outstanding | 0,0.00 | |||
| Number Of Employees | 0,0.00 | |||
| Number Of Part-Time Employees | 0,0.00 | |||
TOTAL REVENUES |
EBT Excluding Unusual Items |
NET INCOME |
|---|---|---|
Income Statement
| M Y | |
|---|---|
| Sales | 0,0.00 |
| Cost Of Sales | 0,0.00 |
| Gross Operating Profit | 0,0.00 |
| Selling, General, And Administrative Expenses | 0,0.00 |
| Research & Development | 0,0.00 |
| Operating Income Before D & A (EBITDA) | 0,0.00 |
| Depreciation & Amortization | 0,0.00 |
| Interest Income | 0,0.00 |
| Other Income - Net | 0,0.00 |
| Special Income / Charges | 0,0.00 |
| Total Income Before Interest Expenses (EBIT) | 0,0.00 |
| Interest Expense | 0,0.00 |
| Pre-Tax Income | 0,0.00 |
| Income Taxes | 0,0.00 |
| Minority Interest | 0,0.00 |
| Net Income From Continuing Operations | 0,0.00 |
| Net Income From Discontinued Operations | 0,0.00 |
| Net Income From Total Operations | 0,0.00 |
| Extraordinary Income/Losses | 0,0.00 |
| Income From Cum. Effect Of Acct. Change | 0,0.00 |
| Income From Tax Loss Carryforward | 0,0.00 |
| Other Gains / Losses | 0,0.00 |
| Total Net Income | 0,0.00 |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0,0.00 |
| Preferred Dividends | 0,0.00 |
| Net Income Available To Common | 0,0.00 |
| Basic EPS From Continuing Ops. | 0,0.00 |
| Basic EPS From Discontinued Ops. | 0,0.00 |
| Basic EPS From Total Operations | 0,0.00 |
| Basic EPS From Extraordinary Inc. | 0,0.00 |
| Basic EPS From Cum Effect Of Accounting Change | 0,0.00 |
| Basic EPS From Tax Loss Carryf'd. | 0,0.00 |
| Basic EPS From Other Gains (Losses) | 0,0.00 |
| Basic EPS, Total | 0,0.00 |
| Basic Normalized Net Income/Share | 0,0.00 |
| EPS From Continuing Ops. | 0,0.00 |
| EPS From Discontinued Ops | 0,0.00 |
| EPS From Total Ops. | 0,0.00 |
| EPS From Extraord. Inc. | 0,0.00 |
| EPS From Cum Effect of Accounting Change | 0,0.00 |
| EPS From Tax Loss Carfd. | 0,0.00 |
| EPS From Other Gains (L) | 0,0.00 |
| EPS, Total | 0,0.00 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0,0.00 |
| Dividends Paid Per Share | 0,0.00 |
CASH FROM OPERATIONS |
CASH FROM INVESTING ACTIVITIES |
CASH FROM FINANCING ACTIVITIES |
|---|---|---|
Cash Flow Statement
| M Y | ||||
|---|---|---|---|---|
| Cash Flow From Operating Activities | ||||
| Net Income (Loss) | 0,0.00 | |||
| Operating Gains/Losses | 0,0.00 | |||
| Gross Operating Profit | 0,0.00 | |||
| (Increase) Decrease In Receivables | 0,0.00 | |||
| (Increase) Decrease In Inventories | 0,0.00 | |||
| (Increase) Decrease In Other Current Assets | 0,0.00 | |||
| (Decrease) Increase In Other Current Liabilities | 0,0.00 | |||
| (Increase) Decrease In Other Working Capital | 0,0.00 | |||
| Other Non-Cash Items | 0,0.00 | |||
| Net Cash From Continuing Operations | 0,0.00 | |||
| Net Cash From Discontinued Operations | 0,0.00 | |||
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | 0,0.00 | |||
| Sale Of Property, Plant & Equipment | 0,0.00 | |||
| Cash Used For Investing Activities | ||||
| Sale Of Short-Term Investments | 0,0.00 | |||
| Purchases Of Property, Plant & Equipment | 0,0.00 | |||
| Acquisitions | 0,0.00 | |||
| Purchases Of Short-Term Investments | 0,0.00 | |||
| Other Cash From Investing Activities | 0,0.00 | |||
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 0,0.00 | |||
| Issuance Of Debt | 0,0.00 | |||
| Cash Used For Financing Activities | ||||
| Issuance Of Capital Stock | 0,0.00 | |||
| Repayment Of Long-Term Debt | 0,0.00 | |||
| Repurchase Of Capital Stock | 0,0.00 | |||
| Payment Of Cash Dividends | 0,0.00 | |||
| Other Financing Charges, Net | 0,0.00 | |||
| Net Cash From Financing Activities | 0,0.00 | |||
| Effect Of Exchange Rate Changes | 0,0.00 | |||
| Net Change In Cash & Cash Equivalents | 0,0.00 | |||
Earnings Estimates
as of 4:00 ET PM 12/02/2021| Current Qtr (12/2021) |
Next Qtr (03/2022) |
|
|---|---|---|
| Consensus Estimate | $3.33 | $4.66 |
| # of Estimates | 26 | 11 |
| High Estimate | $4.21 | $5.79 |
| Low Estimate | $2.65 | $3.13 |
| Year Ago EPS | $2.33 | $2.70 |
| Year Over Year Growth Estimate | 43.01% | 72.73% |
| Current Yr (12/2021) |
Next Yr (12/2022) |
|
|---|---|---|
| Consensus Estimate | $19.16 | $19.06 |
| # of Estimates | 28 | 28 |
| High Estimate | $19.99 | $24.41 |
| Low Estimate | $18.60 | $15.45 |
| Year Ago EPS | $33.70 | $19.16 |
| Year Over Year Growth Estimate | -43.13% | -0.52% |
| Current Qtr (12/2021) |
Next Qtr (03/2022) |
Current Year (12/2021) |
Next Year (12/2022) |
|
|---|---|---|---|---|
| Consensus Estimate | $3.33 | $4.66 | $19.16 | $19.06 |
| # of Estimates | 26 | 11 | 28 | 28 |
| High Estimate | $4.21 | $5.79 | $19.99 | $24.41 |
| Low Estimate | $2.65 | $3.13 | $18.60 | $15.45 |
| Year Ago EPS | $2.33 | $2.70 | $33.70 | $19.16 |
| Year Over Year Growth Estimate | 43.01% | 72.73% | -43.13% | -0.52% |
Insider Information Summary
as of 11/30/2021| % Insiders - 0.38% | |
| % Remaining Total Shares - 99.62% |
| Current | 1 Month | |
|---|---|---|
| Net Insider Transaction | 3.42 K | 3.42 K |
| Shares Bought | 6.01 K | 6.01 K |
| Shares Sold | 2.58 K | 2.58 K |
Insider Activity
| Transaction Date | Insider/Title | Transaction Type | Market Value | Shares | Average Price | Current Holdings | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Learn to Trade Like a Pro
Master The Market with the Help of Our Financial Experts
LATEST NEWS
Biogen's Alzheimer's Drug Gets Negative European Vote
Nov 17, 2021 8:45 AM EST
Latest News
Bargain Shoppers Can Buy The Dip in These 4 Other Sectors
Nov 16, 2021 5:45 PM EST
Stocks End Higher on Johnson & Johnson Spin-Off, Down for the Week
Nov 12, 2021 2:00 PM EST
Johnson & Johnson Spin-Off Powers Dow; Tech Stocks Gain As Treasury Yields Ease
Nov 12, 2021 7:31 AM EST
Biogen Stock Jumps On Positive Data From Aduhelm Alzheimer’s Drug Trial
Nov 12, 2021 6:23 AM EST
The Case For a Biotech Snapback
Nov 2, 2021 6:51 PM EDT
Athira Pharma Stock Climbs on Alzheimer's Test as CEO Resigns
Oct 22, 2021 4:31 PM EDT
Premarket Movers Wednesday - Novavax, Biogen, Netflix
Oct 20, 2021 8:45 AM EDT
Biogen Beats on Third Quarter Earnings and Raises Guidance
Oct 20, 2021 8:41 AM EDT
5 Top Stock Decliners for Monday: Disney, Zillow, Biogen
Oct 18, 2021 3:55 PM EDT
Stocks End Mixed as Strong Earnings Offset Weak China GDP
Oct 18, 2021 3:27 PM EDT
Biogen Stock Drops as ALS Treatment Fails Phase 3 Study
Oct 18, 2021 1:00 PM EDT
Stock Futures Slip, China Slows, Apple 'Unleashed', Delta-Plus Mutation - 5 Things You Must Know
Oct 18, 2021 6:15 AM EDT
Tim Collins Predicts Big Things for Ginkgo Bioworks
Oct 13, 2021 4:06 PM EDT
Real Money Post Industrial Average Outperforms
Oct 6, 2021 1:49 PM EDT
Lilly Stock Upgrades to Buy from Neutral After Shares Decline
Sep 29, 2021 2:18 PM EDT
Premarket Movers Thursday - Darden, Salesforce, Biogen, BlackBerry
Sep 23, 2021 8:30 AM EDT
Cassava Sciences Stock Plummets on Request to Halt Drug Trials
Aug 25, 2021 8:41 AM EDT
TheStreet Live Recap: Everything Jim Cramer Is Watching 7/22/21
Jul 22, 2021 2:02 PM EDT
Jim Cramer on Biogen Earnings, Alzheimer's Drug
Jul 22, 2021 11:11 AM EDT
Video: Jim Cramer on AT&T, Airline Earnings, Biogen, Crypto, Uber
Jul 22, 2021 9:48 AM EDT
Premarket Movers Thursday: CSX, Texas Instruments and AT&T
Jul 22, 2021 8:22 AM EDT
Dow Futures Pare Gains On Inflation Concerns; Jobless Claims Rise to 419,000
Jul 22, 2021 5:52 AM EDT
Tesla and Bitcoin, Activision, AT&T, Chembio - 5 Things You Must Know
Jul 22, 2021 5:04 AM EDT
Recent Articles from TheStreet
Microsoft Awaits UK Regulator on Rivals' Complaints, Report Says
The Competition and Markets Authority reportedly has been meeting with Microsoft's tech competitors to gauge their concerns about the Seattle company's business behavior.
Bob Dole, Former GOP Presidential Nominee and Senate Leader, Dies
Former Republican presidential nominee and U.S. Senate leader Bob Dole dies at 98.
AMC Stock: What to Expect From the Domestic Box Office
The movie business has changed and that's not good for AMC shareholders.
Pear Therapeutics Stock to Begin Trading After SPAC Merger
Pear Therapeutics received its second breakthrough device designation from the Food and Drug Administration for its reSET-A product candidate that is designed for the treatment of alcohol substance use disorder.
Elon Musk's SpaceX Building Starship Launch Pad for Mars, Moon Trips
SpaceX CEO Elon Musk tweets Saturday that the company has started construction on an orbital launch pad at the Kennedy Space Center in Florida for missions to the Moon and Mars.
What's Next for Planet 13: A U.S. Listing, Chicago, and Florida
The company solidifies its hold on Nevada while launching its California Superstore and planning a U.S. stock listing as well as moves into Chicago and Florida.
Robot Vacuums, Air Fryers, Hermes Bags: What Shoppers Bought Cyber Monday
Based on Cyber Mondays sales, robot vacuums are on a lot of holiday gift lists this year, with sales of the home appliances up 2,250% from last year.
Market Dancing Like a 'Puppet on a String'
In the current state of the world, investors are ignoring two key truths, Jim Collins says.
Cramer's Mad Money Recap 12/3: DocuSign, GameStop, Costco
Valuations for many stocks are high, says Jim Cramer. That means investors should be on the lookout for potential shocks and new buying opportunities.
The Bear is Hiding in Plain Sight
James 'Rev Shark" Deporre says the disconnect between mega cap stocks holding up the market indexes and struggling shares of many other companies is only getting worse.